A dose-response evaluation of ALK tree AIT

Trial Profile

A dose-response evaluation of ALK tree AIT

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Birch pollen allergy immunotherapy (Primary)
  • Indications Allergic rhinoconjunctivitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ALK-Abello
  • Most Recent Events

    • 15 Mar 2018 Results (n=637) assessing of birch pollen allergy immunotherapy [ALK tree AIT] versus placebo in patients with moderate to severe birch pollen induced allergic rhinoconjunctivitis, were published in the Clinical Therapeutics.
    • 08 Nov 2013 Status changed from active, no longer recruiting to completed, according to a media release.
    • 15 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top